Hot flushes, poor sleep, changes in the menstrual cycle or unfamiliar inner restlessness can significantly affect daily life. At the same time, not every new symptom is automatically caused by hormones. Thyroid disease, depression, medication or cardiovascular risk factors can produce similar symptoms. A sound assessment therefore begins with the individual situation: which symptoms are new, how are they changing, how much do they interfere with life and which other causes need to be considered?
Menopause is neither a single diagnosis nor a uniform experience. Some women mainly notice changes in bleeding, while others experience vasomotor symptoms such as hot flushes and sweating. Sleep, mood, joints, sexuality and symptoms involving the vagina or urinary tract may also matter. The purpose of a medical consultation is not to attribute as many changes as possible to hormones, but to recognise patterns, exclude warning signs and decide together which support fits the individual burden.
What do perimenopause, menopause and postmenopause mean?
Perimenopause is the transition around the final menstrual period. Cycle length may fluctuate, bleeding may become less regular and typical symptoms may newly appear. Menopause itself refers retrospectively to the final spontaneous menstrual period. In women over 45 with a previously assessable bleeding pattern, a postmenopausal state is considered likely after at least twelve months without a period. Postmenopause is the stage that follows. These terms help with timing, but by themselves they do not indicate symptom severity or the right treatment.
The transition can be harder to recognise when bleeding patterns cannot be assessed, for example after certain operations or while using hormonal contraception. An early onset also changes the diagnostic question. An age range found online is therefore no substitute for medical history and examination. What matters is the combination of cycle course, symptoms, existing conditions, medication and individual risk. Unexpected or severely troubling changes should not be classified on the basis of a single laboratory value alone.
Which symptoms may be related to menopause?
Hot flushes and sweating are particularly characteristic. Sleep disturbance, muscle and joint symptoms, mood changes and altered sexual function are also reported. Dry mucous membranes, pain during intercourse, urinary urgency or recurrent urinary symptoms may form part of the genitourinary syndrome of menopause. Symptoms can occur alone or together and may change over time. Intensity matters more than a long checklist: treatment becomes relevant especially when quality of life, daily activities, relationships or functioning are meaningfully affected.
A symptom diary can reveal patterns. Useful entries include bleeding, hot flushes, sleep, mood, pain, medication and possible triggers. It should not, however, be used to explain every change as hormonal. New fatigue, for example, may also relate to anaemia, thyroid disease, infection, sleep apnoea or depression. Marked pain, neurological symptoms and persistent loss of function likewise deserve assessment in their own right. Menopause should not replace a differential diagnosis.
When are hormone tests and further investigations useful?
With a typical course, the stage can often be assessed clinically from age, bleeding pattern and symptoms. Hormone levels fluctuate during perimenopause and may suggest a certainty that the biology does not provide. Targeted laboratory testing may be useful when the bleeding pattern cannot be assessed, symptoms occur unusually early or other causes need to be investigated. Which tests are appropriate follows from the specific question. A blanket hormone panel for every woman is therefore not a reliable shortcut.
PRECIOUS offers menopause consultation in Wiesbaden with hormone diagnostics, individual treatment and holistic support. Hormone diagnostics does not automatically mean measuring every available value. A stepwise approach is useful: first record symptoms, bleeding history, medication and personal and family risks, then direct examination and laboratory tests towards the unresolved question. In this way, diagnostics can help without allowing a single measurement to define an entire life stage or treatment decision.
When can menopausal hormone therapy help?
Menopausal hormone therapy, or MHT, is an effective treatment option for troublesome vasomotor symptoms. Whether it is suitable depends on more than the symptom alone. Uterine status, age and time since menopause, bleeding history, breast cancer risk, thrombosis, stroke and cardiovascular risks, as well as other conditions, belong in the decision. Route of administration and dose may also influence the risk profile. MHT is therefore neither inherently dangerous nor universally safe.
Before treatment begins, the goal, expected benefit, possible risks and alternatives should be discussed in understandable terms. When the uterus is present, systemic oestrogen therapy generally requires adequate protection of the endometrium with a progestogen; after hysterectomy, this question is different. The specific medicine and dose are medical decisions. It is also important not to broaden the indication: MHT should not be started as general prevention for cardiovascular disease or dementia.
Which non-hormonal options are available?
If MHT is not wanted, not tolerated or medically unsuitable, other approaches may be considered according to the symptom. Cognitive behavioural therapy can support sleep and coping with symptoms. Certain prescription non-hormonal medicines are also available for vasomotor symptoms. Choice and monitoring depend on existing conditions, interactions and licensing. Exercise, balanced nutrition, smoking cessation and good sleep remain important for general health, but they do not replace effective symptom treatment when the burden is high.
Herbal does not automatically mean effective or risk-free. Evidence for isoflavones, black cohosh and other products differs by treatment goal and is sometimes of low certainty. Products may vary in composition and dose, and interactions and contraindications are possible. A blanket recommendation from a shop shelf does not reflect this uncertainty. Anyone considering a product should bring its exact name and a complete medication list to the consultation.
What can help with vaginal dryness and urinary symptoms?
Dryness, burning, pain during intercourse, urinary urgency or recurrent urinary symptoms are not simply an inevitable part of ageing that must be accepted. They may be part of the genitourinary syndrome of menopause. Non-hormonal moisturisers and lubricants can relieve symptoms. After medical assessment, local oestrogen therapy may also be considered for symptoms of vulvovaginal atrophy. Local and systemic treatment pursue different goals and should not automatically be treated as equivalent.
Bleeding after menopause, visible blood in the urine, recurrent infections, unusual discharge or new severe pain require assessment in their own right. Symptoms should not be attributed solely to mucosal change before other causes have been considered. A respectful sexual history is equally important: pain, changes in desire and relationship strain often have several physical and psychosocial influences. Treatment should follow the specific problem, not a general promise of rejuvenation.
What role do bone and cardiovascular health play?
Bone density may decline during the menopausal transition and afterwards. Individual fracture risk, however, depends on more than hormone status, including previous fractures, family history, medication, smoking, body weight and other conditions. Whether bone-density testing or targeted prevention is needed is decided from this risk profile. MHT may provide an additional bone benefit when it is being considered for an appropriate indication. It is not a universal prevention programme for every woman.
Blood pressure, blood lipids, diabetes risk, smoking and physical activity also deserve attention. Cardiovascular and cerebrovascular risks should be assessed individually before oestrogen therapy. This does not mean every woman needs the same investigations. It means symptom treatment is not planned separately from overall health. Prevention remains a task in its own right: identify risk, manage modifiable factors and use age-appropriate preventive care rather than attributing blanket protection to hormone therapy.
Which warning signs need prompt assessment?
- any bleeding after menopause, as well as unusually heavy or persistent bleeding
- chest pain, acute shortness of breath, one-sided leg swelling or sudden neurological symptoms
- severe depressive symptoms, suicidal thoughts or rapid deterioration in mental health
- new severe pain, unintended weight loss, persistent fever or marked decline in functioning
These signs are not a typical menopause checklist, but reasons for prompt or urgent medical assessment. Possible emergency symptoms should not wait for a routine consultation. Less dramatic symptoms also deserve attention if they worsen or substantially interfere with daily life. Safe menopause care recognises its limits: it assesses typical changes while remaining alert to symptoms that need a different diagnostic pathway or multidisciplinary treatment.
How can you prepare for a menopause consultation?
- Record bleeding history, the main symptoms, onset, frequency and impact.
- Bring a complete list of medicines, hormones and supplements.
- Note personal and family risks such as thrombosis, cardiovascular disease, osteoporosis and cancer.
- Define a specific treatment goal and which risks or forms of treatment concern you.
A good decision may mean hormonal treatment, non-hormonal treatment, local therapy, further investigations or observation for the time being. PRECIOUS is a private practice for internal medicine, longevity and aesthetic medicine in Wiesbaden. Billing is private under the German medical fee schedule, GOÄ. Contact is possible by telephone, WhatsApp or email, and online booking via Doctolib is available around the clock. The focus should not be a method selected in advance, but a clearly described problem and a jointly weighed goal.
Sources
AWMF: S3 Guideline on Perimenopause and Postmenopause – Diagnosis and Treatment, registration number 015-062, update draft June 2026.
Full citation: Hemachandra C, Taylor S, Islam RM, Fooladi E, Davis SR. A systematic review and critical appraisal of menopause guidelines. BMJ Sexual and Reproductive Health. 2024;50(2):122–138. PMID 38336466.
